Intelligencia, Inc.

Founded in 2017, Intelligencia, Inc. is a New York-based company that provides advanced artificial intelligence solutions for the pharmaceutical industry, focusing on optimizing drug development processes. Intelligencia, Inc. specializes in artificial intelligence tools for the pharmaceutical sector, enhancing decision-making through success probability assessments for drugs.

The company was founded in 2017 in New York, US, by Dimitrios Skaltsas, who has a background in technology and entrepreneurship. The company secured a SERIES A funding round in August 2021, raising USD 12. 000 mn, led by MTIP, with participation from Big Pi Ventures, Synetro Group, and ZS Associates, marking the single investment deal to date. Intelligencia AI specializes in providing advanced artificial intelligence solutions tailored for the pharmaceutical industry, specifically focused on drug development optimization.

The company's core offerings include a suite of tools designed to enhance clinical decision-making by assessing the probability of success (PoS) for drugs across various therapeutic areas. These solutions facilitate risk identification, streamline clinical trial design, and enable access to harmonized data for consistent evaluations. Clients benefit from comprehensive data insights, leveraging proprietary ontologies and expert data curation, which are utilized by leading pharmaceutical organizations globally. Intelligencia AI’s products are primarily marketed across North America and Europe, addressing the needs of both large pharmaceutical companies and emerging biotech firms.

Intelligencia AI generates revenue through a subscription-based model that provides access to its suite of software-as-a-service (SaaS) products, including the Portfolio Optimizer and Dynamic Benchmarks. Clients engage in business transactions by subscribing to these services, which offer advanced insights and predictive analytics for clinical development projects. The company fosters partnerships with pharmaceutical organizations, enabling them to utilize accurate and transparent PoS assessments at various stages of drug development. Revenue is driven by long-term commitments from clients who rely on Intelligencia AI’s solutions for real-time tracking and validation of clinical programs, emphasizing the integral role of these tools in their operational frameworks.

Intelligencia, Inc. plans to utilize the USD 12. 000 mn raised in its SERIES A funding round in August 2021 to expand its product offerings, enhance its proprietary data, and grow its customer base. The company is actively working on new product designs that will be unveiled in the coming year, aiming to strengthen its position in the market.

Additionally, Intelligencia intends to expand its reach into new geographic markets, notably aiming to increase its presence in Asia-Pacific by 2023.